483
Samsung Biologics Co., Ltd.Samsung Biologics Co., Ltd. – FDA 483, Mar 14, 2018
Record Details
An FDA inspection of Samsung Biologics in Incheon, Republic of Korea, identified significant deficiencies in quality assurance oversight and pest control. The firm lacked adequate risk assessment for drug substance intermediates, improperly stored micro testing media, and inadvertently discarded critical bioburden samples. Additionally, the pest control program was deemed inadequate due to variable alert and action limits.
View Company Profile
ID · ce260ba9-5da0-4986-9b6e-3fee4fc334d5
Other documents for Samsung Biologics Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.